North Carolina residents may be interested to hear that a recent mesothelioma clinical trial reveals that cryotherapy may be a valuable addition to multidisciplinary treatments of pleural mesothelioma. A leading thoracic surgeon believes that the groundbreaking clinical trial is promising for mesothelioma patients. Although more tests are needed, she says that it could play an important role in future treatments.
In the past few years, there has been a surge of lawsuits filed against Johnson & Johnson, a well-known and respected brand, for asbestos exposure and related cancers. Plaintiffs claim that due to contaminated baby powder products, they were at heightened risk of contracting deadly cancers.
For many years, the use of asbestos in the construction industry was quite common. In the past, this was used as both an insulating material and flame retardant.
Mesothelioma is an aggressive form of cancer that is caused by asbestos exposure. Many victims will live for decades without a disease diagnosis because they do not exhibit mesothelioma symptoms. By the time they are diagnosed with peritoneal or pleural mesothelioma, treatment symptoms are limited, and life expectancy is decreased.
The news broke last month that at least one national retailer - whose targeted demographic group is adolescent girls and young women - was found to be selling potentially cancer-causing makeup. This revelation came in the midst of the holiday sales crush, when consumers were flocking to malls and stores for last-minute gifts for friends and loved ones.
Malignant mesothelioma is a disease often contracted from occupational exposure to asbestos. The latency period for the disease is approximately 20 to 40 years, sometimes as long as 71 years. Therefore, despite increased regulation of asbestos, more North Carolinians are discovering that they have mesothelioma due to their exposure to asbestos decades earlier.
North Carolinians would likely be interested in a new mesothelioma study. The study, conducted by Johns Hopkins and Drexel University, reveals that survivors of mesothelioma and other cancers may not be following appropriate dietary guidelines to increase their survivability. Participants in the study -- 53 survivors of breast, prostate and non-Hodgkin's lymphoma -- were asked to track their diets over three days.
Mesothelioma Awareness Day, established by Meso Foundation community members, will take place on September 26 for the 13th year in a row. The campaign is designed to bring awareness and funding to mesothelioma, a disease that claims the lives of thousands each year. The disease has a mortality rate of nearly 64 percent within one year.
A recent study by researchers at the MD Anderson Cancer Center confirms what many North Carolina residents suffering from mesothelioma already know -- mesothelioma patients benefit greatly from undergoing several forms of treatment. The study's researchers found that post-disease diagnosis patients, who undergo multimodal treatment, live almost twice as long as those who do not.
Mesothelioma patients may be disappointed to learn that a trial of a new mesothelioma drug, anetumab ravtansine, was stopped after the drug was proven to be less effective than an existing drug, vinorelbine. The results of Bayer's Phase II clinical trial showed that the new drug designed to treat recurrent malignant mesothelioma did not slow progression of mesothelioma better than vinorelbine and therefore the trial did not meet its primary endpoint.